Robert Bessler Sells 119,942 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 119,942 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the sale, the director directly owned 1,318,983 shares in the company, valued at $9,285,640.32. This trade represents a 8.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Robert Bessler also recently made the following trade(s):

• On Monday, December 22nd, Robert Bessler sold 1,701 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.04, for a total transaction of $11,975.04.
• On Thursday, December 18th, Robert Bessler sold 6,442 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $45,094.00.
• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $86,597.00.
• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total value of $558,206.30.

LifeStance Health Group Stock Up 0.5%

Shares of LFST opened at $7.10 on Thursday. The firm has a market cap of $2.76 billion, a P/E ratio of -236.50 and a beta of 1.13. LifeStance Health Group, Inc. has a 12 month low of $3.74 and a 12 month high of $8.30. The stock’s 50 day moving average is $6.11 and its two-hundred day moving average is $5.39. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The business had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. During the same period in the prior year, the company posted ($0.02) EPS. The business’s quarterly revenue was up 16.3% on a year-over-year basis. Analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LFST. Park Edge Advisors LLC acquired a new stake in shares of LifeStance Health Group in the 2nd quarter worth $52,000. Bayesian Capital Management LP acquired a new position in shares of LifeStance Health Group during the 2nd quarter valued at about $52,000. Public Employees Retirement System of Ohio purchased a new stake in shares of LifeStance Health Group in the second quarter valued at about $70,000. Blair William & Co. IL purchased a new stake in shares of LifeStance Health Group in the second quarter valued at about $70,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in LifeStance Health Group during the third quarter worth about $72,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on LFST. Barclays initiated coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They set an “overweight” rating and a $8.00 target price for the company. UBS Group increased their target price on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 7th. BMO Capital Markets assumed coverage on LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price target on the stock. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Finally, Wall Street Zen lowered LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.83.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.